Professor, Medicine, Oregon Health and Science University School of Medicine

Infectious Disease

Dr. David N. Gilbert works in the field of Infectious Disease. He attended Oregon Health & Science University School of Medicine. He received 1 awards: "Top MD". David Gilbert is also published. He has 43 publications published. The lastest publication: "Comparison of amikacin and gentamicin in the treatment of urinary tract infections.'

Publications

---

• Novel approaches are needed to develop tomorrow's antibacterial therapies.
• The future of antibiotics and resistance: a tribute to a career of leadership by john bartlett.
• Scenario 1: a patient with mild community-acquired pneumonia--introduction to clinical trial design issues.
• Clinical end points of therapy for patients with mild community-acquired pneumonia.
• Mycobacterium gordonae in fiberoptic bronchoscopes.
• Staphylococcus aureus septic arthritis in patients on hemodialysis treatment.
• Pig kidney (LLC-PK1) cell membrane fluidity during exposure to gentamicin or tobramycin.
• Infectious Diseases Society of America and health care reform.
• Aminoglycoside-induced increase of intracellular calcium in LLC-PK1 cells due to an artifact caused by trypsin and EDTA.
• European guidelines for anti-infective drug products. Introduction.
• Pharmacologic limits of the protective effect of polyaspartic acid on experimental gentamicin nephrotoxicity.
• Determinants of the in vitro interaction of polyaspartic acid and aminoglycoside antibiotics.
• General guidelines for the clinical evaluation of anti-infective drug products. Infectious Diseases Society of America and the Food and Drug Administration.
• Evaluation of new anti-infective drugs for the treatment of infective endocarditis. Infectious Diseases Society of America and the Food and Drug Administration.
• Duration of the protective effect of polyaspartic acid on experimental gentamicin nephrotoxicity.
• Zidovudine pharmacokinetics in five HIV seronegative patients undergoing continuous ambulatory peritoneal dialysis.
• Long-term protection of polyaspartic acid in experimental gentamicin nephrotoxicity.
• The path to new FDA guidelines for clinical evaluation of anti-infective drugs.
• Once-daily aminoglycoside therapy.
• Failure of treatment with teicoplanin at 6 milligrams/kilogram/day in patients with Staphylococcus aureus intravascular infection. The Infectious Diseases Consortium o...
• The implications for Europe of revised FDA guidelines for clinical trials with anti-infective agents.
• Meningitis due to penicillin-resistant Streptococcus pneumoniae in adults.
• Use of antimicrobial agents in renal failure.
• Influence of daptomycin on staphylococcal abscesses and experimental tobramycin nephrotoxicity.
• Polyaspartic acid prevents experimental aminoglycoside nephrotoxicity.
• Is it really a fungal infection?
• Microsomal protein synthesis inhibition: an early manifestation of gentamicin nephrotoxicity.
• The influence of tobramycin dosage regimens on nephrotoxicity, ototoxicity, and antibacterial efficacy in a rat model of subcutaneous abscess.
• Guidelines for evaluating new antimicrobial agents.
• Oral ciprofloxacin therapy for chronic contiguous osteomyelitis caused by aerobic gram-negative bacilli.
• New sodium hydroxide digestion method for measurement of renal tobramycin concentrations.
• Vancomycin enhancement of experimental tobramycin nephrotoxicity.
• Attenuation of experimental tobramycin nephrotoxicity by ticarcillin.
• Nephrotoxicity of the constituents of the gentamicin complex.
• The influence of aminoglycoside antibiotics on the in vitro function of rat liver ribosomes.
• Gentamicin does not chelate calcium.
• Failure of lysine to prevent experimental gentamicin nephrotoxicity.
• Amikacin nephrotoxicity in the rat.
• Comparison of amikacin and gentamicin in the treatment of urinary tract infections.
• The bacterial causation of postoperative osteitis pubis.
• Microbiologic study of wound infections in tornado casualties.
• Influence of an infectious diseases specialist on ICU multidisciplinary rounds.

Schools

---

• Oregon Health Sciences University

• Dallas Co Hp Parkland Mem

• Hennepin Co Med Center

• Or Health Science University Hospital

Doctors Specialties

---

• Infectious Disease Medicine
• Infectious Disease

Accepted Insurances

---

• Aetna
• Blue Card PPO
• Great West Healthcare-Cigna PPO
• Commercial Insurance Company
• CoreSource
• First Choice Health
• Medicare Advantage PFFS
• Humana
• MedHealthInsurance
• Medicare MCR
• National Elevator
• PacificSource
• PHP-Physicians Health Plan
• Heritage Plus
• Heritage Signature
• Preferred Provider Network PPN
• Tricare
• United Healthcare

Awards

---

• Top MD

Education

---

• Oregon Health & Science University
• Hennepin County Medical Center
• Oregon Health & Science University School of Medicine

Hospital

---

• Providence Portland Medical Center
• Providence St. Vincent Medical Center

Helpful Reviews

---

Give Anonymous Review

Similar Doctors

---

	Dr. Erin E. McNelley, MD This Doctor is OpenDoctor Recommended.
	Dr. Adam C. Brady, MD This Doctor is OpenDoctor Recommended.
	Dr. James E. Leggett Jr., MD This Doctor is OpenDoctor Recommended.
	Dr. Cameron J. Cover, MD This Doctor is OpenDoctor Recommended.
	Dr. Amy M. Dechet, MD This Doctor is OpenDoctor Recommended.
	Dr. Jean Y. Rim, MD This Doctor is OpenDoctor Recommended.
	Dr. Robert C. Lusk, MD This Doctor is OpenDoctor Recommended.
	Dr. Nancy J. Macneal, MD This Doctor is OpenDoctor Recommended.
	Dr. Lynne M. Strasfeld, MD This Doctor is OpenDoctor Recommended.
	Dr. Charles M. Kilo, MD This Doctor is OpenDoctor Recommended.
	Dr. Sarah Slaughter, MD This Doctor is OpenDoctor Recommended.
	Dr. Rebecca E. Chandler, MD This Doctor is OpenDoctor Recommended.
	Dr. John M. Townes, MD This Doctor is OpenDoctor Recommended.
	Dr. Brian Wong, MD This Doctor is OpenDoctor Recommended.

---

Doctor Directory | TOS | twitter | FB | Angel | blog